浙江医学2018，Vol.40Issue(1)：47-49,3.DOI:10.12056/j.issn.1006-2785.2017.40.1.2017-584
非布司他联合秋水仙碱对高尿酸血症患者血清NALP3、IL-1β的影响
Efficacy of colchicine combined with febuxostat versus colchicines with allopurinol in treatment of patients with hyperuricemia
摘要
Abstract
Objective To evaluate the efficacy of colchicine combined with febuxostat in treatment of patients with hyperuricemia.Methods Eighty six patients with hyperuricemia were randomly assigned to two groups with 43 cases in each group.Patients in control group were treated by colchicine combined with allopurinol and those in study group were treated by colchicine combined with febuxostat.The serum levels of BUA,Scr,BUN,NALP3 and IL-1β were compared between the two groups before and after treatment.The adverse reactions of two groups were recorded during the treatment.Results The curative effect of study group was significantly better than that of control group (P＜0.05).After treatment,the BUA,NALP3 and IL-1β levels in both groups were significantly lower than those before treatment (P＜0.05),while Scr and BUN levels did not change significantly before and after treatment(P ＞0.05).After treatment,the BUA,NALP3 and IL-1β levels in study group were significantly lower than those in control group (P＜0.05).The incidence of adverse reactions in study group (16.28％) was significantly lower than that in control group (25.58％,P＜0.05).Conclusion Febuxostat combined with colchicine is more effective than allopurinol in treatment of patients with hyperuricemia,which is associated with reduced serum IL-1 and NALP3 levels.关键词
非布司他片/秋水仙碱/高尿酸血症/核苷酸结合寡聚化结构域样受体3/IL-1βKey words
Febuxostat tablets/Colchicines/Hyperuricemia/NALP3/IL-1β引用本文复制引用
施卫民,叶露敏,王文琴..非布司他联合秋水仙碱对高尿酸血症患者血清NALP3、IL-1β的影响[J].浙江医学,2018,40(1):47-49,3.
